Teva Seeks To Invalidate Insomnia Drug IP In Neurim Suit

By Silvia Martelli ( April 4, 2022, 4:14 PM BST) -- Teva has hit back at Neurim's lawsuit accusing the generic giant of infringing its patent for an insomnia treatment, arguing that its fellow Israeli drugmaker's intellectual property is invalid....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login